These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 23233631)

  • 1. New oral anticoagulants: which one should my patient use?
    Weitz JI; Gross PL
    Hematology Am Soc Hematol Educ Program; 2012; 2012():536-40. PubMed ID: 23233631
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disadvantages of VKA and requirements for novel anticoagulants.
    Shameem R; Ansell J
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):103-14. PubMed ID: 23953899
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [New anticoagulants: dabigatran, rivaroxaban and apixaban].
    Vargas Ruiz AG; Ramírez López AN; Medina Viramontes ME
    Gac Med Mex; 2012; 148(3):257-64. PubMed ID: 22820359
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel oral anticoagulants in secondary prevention of stroke.
    Diener HC; Easton JD; Hankey GJ; Hart RG
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):131-9. PubMed ID: 23953901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel oral anticoagulants for thromboprophylaxis after orthopaedic surgery.
    Quinlan DJ; Eriksson BI
    Best Pract Res Clin Haematol; 2013 Jun; 26(2):171-82. PubMed ID: 23953905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New oral anticoagulants in the treatment of venous thromboembolic disease].
    Calvo Romero JM; Lima Rodríguez EM
    Semergen; 2013 Apr; 39(3):146-9. PubMed ID: 23540987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.
    Cheng JW; Barillari G
    J Clin Pharm Ther; 2014 Apr; 39(2):118-35. PubMed ID: 24383983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory monitoring of anticoagulant medications: focus on novel oral anticoagulants.
    Baruch L
    Postgrad Med; 2013 Mar; 125(2):135-45. PubMed ID: 23816779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New oral anticoagulant drugs: dabigatran, rivaroxaban and apixaban. Present and future].
    Dumont B; Faille D; Ajzenberg N
    Med Sci (Paris); 2011 May; 27(5):493-500. PubMed ID: 21609670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel anticoagulants and laboratory testing.
    Eby C
    Int J Lab Hematol; 2013 Jun; 35(3):262-8. PubMed ID: 23590653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new era of anticoagulation.
    Hainaut PH
    Acta Clin Belg; 2012; 67(6):394-8. PubMed ID: 23340143
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of new oral anticoagulant drugs: dabigatran and rivaroxaban.
    Baglin T
    Br J Haematol; 2013 Oct; 163(2):160-7. PubMed ID: 23937286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
    Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
    Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of oral anticoagulants in patients with atrial fibrillation.
    Greenspon AJ
    Postgrad Med; 2012 Nov; 124(6):7-16. PubMed ID: 23322134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
    Fenger-Eriksen C; Münster AM; Grove EL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond unfractionated heparin and warfarin: current and future advances.
    Hirsh J; O'Donnell M; Eikelboom JW
    Circulation; 2007 Jul; 116(5):552-60. PubMed ID: 17664384
    [No Abstract]   [Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.